A prospective open label randomised multicentre study evaluating the efficacy and safety of rituximab given pre-transplant to sensitised renal allograft recipients in addition to a standard desensitisation regimen consisting of PE/IVIG and MMF.
Phase of Trial: Phase II
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Rituximab (Primary)
- Indications Renal transplant rejection
- Focus Therapeutic Use
- Acronyms RAPTURE
- 22 Oct 2006 New trial record.